GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

I-MAB (IMAB) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Jun. 08, 2024)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, I-MAB's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.


Competitive Comparison of I-MAB's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, I-MAB's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


I-MAB's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where I-MAB's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.



I-MAB  (NAS:IMAB) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


I-MAB Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of I-MAB's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.


I-MAB (IMAB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Traded in Other Exchanges
Address
555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.